Skip to content
Screener

Novavax NVAX Business Segments — Total Revenue

Similar metrics at other companies

NSA
NSAReportable Segment — Total Revenue
$185.4M-1.6%
Lemonade logo
LMNDReportable Segment — Total Revenue
$258M+70.6%
Casey's General Stores logo
CASYReportable Segment — Total Revenue
$4.57B+14.5%
RB Global logo
RBAReportable Segment — Total Revenue
$1.23B+11.4%
Biogen logo
BIIBReportable Segment — Total Revenue
$2.74B+3.4%
ARD
ARDTReportable Segment — Total Revenue
$1.62B-1.4%

Other financials

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation

See full
Market cap$1.27B+3.7%
Enterprise value$1.38B+33.6%
P/S3.1×+1.9×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp
FCF margin-59%-61.5pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.3×0.0×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Novavax’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001000694-26-000018
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue$56,698$239,240$196,212$905,895
Cost of sales14,24615,32544,94129,439
Research and development expenses:
Direct COVID-19 Vaccine(1)20,07313,07754,32828,824
Direct CIC and influenza vaccines7037,1173,55619,621
Direct other vaccine development programs(1)3,1298425,393997
Employee and benefit expenses30,82036,14968,87576,060
Facility and other research and development expenses(2)15,96822,04834,01342,668

Item 1. Consolidated Financial Statements

FAQ

What is Novavax's business segments — total revenue?
Novavax (NVAX) reported business segments — total revenue of $56.7M in Q2 2026.
How has Novavax's business segments — total revenue changed year-over-year?
Novavax's business segments — total revenue decreased by 76.3% year-over-year, from $239.24M to $56.7M.
What is the long-term trend for Novavax's business segments — total revenue?
Over 3 years (2022 to 2025), Novavax's business segments — total revenue has grown at a -17.2% compound annual growth rate (CAGR), from $1.98B to $1.12B.
What does business segments — total revenue mean?
Represents the total gross income generated by the company's primary reportable business segment through the sale of products and services. This metric reflects the market demand for the segment's offerings and serves as a key indicator of its top-line growth and commercial performance.

Ask your AI about Novavax's business segments — total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude